Predicting treatment responses to IV immunoglobulins: can we already ask the genes?
Helmar C
HC
Lehmann
Bernd C
BC
Kieseier
D001369:Axons / Q000378:metabolism; D015415:Biomarkers; D015816:Cell Adhesion Molecules, Neuronal / Q000235:genetics / Q000378:metabolism; D058969:Contactin 2; D055106:Genome-Wide Association Study; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007155:Immunologic Factors / Q000627:therapeutic use*; D015213:Neuroimmunomodulation / Q000235:genetics / Q000502:physiology; D020641:Polymorphism, Single Nucleotide; D020277:Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics*; D011379:Prognosis; D012583:Schwann Cells / Q000378:metabolism; D016896:Treatment Outcome
D015415:Biomarkers; C548674:CNTN2 protein, human; D015816:Cell Adhesion Molecules, Neuronal; D058969:Contactin 2; D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors